-+ 0.00%
-+ 0.00%
-+ 0.00%

Baike Biotech announced that the company recently received the “Notice of Acceptance” of the clinical trial application for a recombinant human antirespiratory syncytial virus monoclonal antibody injection combination formulation issued by the State Drug Administration. The application is a registered clinical trial for domestically produced drugs. The acceptance number is CXSL2601038, which was accepted after review. This product is used to prevent lower respiratory tract infections caused by RSV in newborns and infants.

Zhitongcaijing·09/22/2026 10:57:13
Listen to the news
Baike Biotech announced that the company recently received the “Notice of Acceptance” of the clinical trial application for a recombinant human antirespiratory syncytial virus monoclonal antibody injection combination formulation issued by the State Drug Administration. The application is a registered clinical trial for domestically produced drugs. The acceptance number is CXSL2601038, which was accepted after review. This product is used to prevent lower respiratory tract infections caused by RSV in newborns and infants.